J Obes Metab Syndr 2022; 31(1): 91-91
Published online March 30, 2022 https://doi.org/10.7570/jomes22016
Copyright © Korean Society for the Study of Obesity.
Ghayoung Lee, Ji Hye Han, Hyo Jin Maeng, Soo Lim
Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Updates have been made to Methods (p. 27): the reason why male rats were selected for the current study has been explained. The original version of the article can be found at https://doi.org/10.7570/jomes19042.
The subsection of “Experimental design and animal care” in the Methods has been revised to read:
Forty male C57BL/6 mice aged 7 weeks (Japan SLC, Shizuoka, Japan) were used in the study. Males were selected to exclude the effect of menstrual cycle. All mice were maintained at a temperature of 22°C±2°C and 55%±10% humidity under a 12:12-hour light-dark cycle and were allowed food and water ad libitum for the duration of the treatment period.
After being matched for weight, study mice were divided into two groups: one group was fed a normal chow diet and the second a high-fat diet. Each group was further divided into four subgroups with various treatments: water, equivalent of two cans of Coca-Cola, equivalent of two cans of Maxwell, and equivalent of two packs of Choco-Latte. Therefore, there were eight groups total, with five mice per group. At 8 AM each day, treatment beverages were administered to study animals using a feeding device. The amount of beverage administered to mice was calculated based on body weight according to a commonly used conversion between humans (60 kg) and mice (20 g). At the end of the 13-week treatment, the mice were anesthetized with an intraperitoneal injection of a mixture of zolazepam/tiletamine (80 mg/kg, Zoletil 50; Virbac, Carros, France) and xylazine (20 mg/kg, Rompun; Bayer HealthCare, Leverkusen, Germany) for euthanasia.
This study was approved by the Institutional Animal Care and Use Committee of Seoul National University Bundang Hospital (No. 51-2015-031). Experiments were performed in compliance with the Guide for Experimental Animal Research of the Laboratory for Experimental Animal Research, Clinical Research Institute, Seoul National University Bundang Hospital, Korea.